Cargando…
P‐Glycoprotein Mediated Drug Interactions in Animals and Humans with Cancer
Drug–drug interactions can cause unanticipated patient morbidity and mortality. The consequences of drug–drug interactions can be especially severe when anticancer drugs are involved because of their narrow therapeutic index. Veterinary clinicians have traditionally been taught that drug–drug intera...
Autores principales: | Mealey, K.L., Fidel, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858061/ https://www.ncbi.nlm.nih.gov/pubmed/25619511 http://dx.doi.org/10.1111/jvim.12525 |
Ejemplares similares
-
Canine and feline P‐glycoprotein deficiency: What we know and where we need to go
por: Mealey, Katrina L., et al.
Publicado: (2022) -
Study Models of Drug–Drug Interactions Involving P-Glycoprotein: The Potential Benefit of P-Glycoprotein Modulation at the Kidney and Intestinal Levels
por: Veiga-Matos, Jéssica, et al.
Publicado: (2023) -
Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein
por: Sajid, Andaleeb, et al.
Publicado: (2020) -
Selective modulation of P-glycoprotein-mediated drug resistance
por: Bebawy, M, et al.
Publicado: (2001) -
Interaction of Docetaxel (“Taxotere”) with Human P‐Glycoprotein
por: Shirakawa, Katsuro, et al.
Publicado: (1999)